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relevance and potential impact on disease man-
agement, including either original papers or spe-
cific reviews. At present there are no updated 
international guidelines on the management of 
pericardial diseases beyond the 2004 guidelines 
issued by the European Society of Cardiology [8].
Etiology of pericarditis in women
Women are more commonly affected by spe-
cific forms of pericarditis related to SID. On 
this basis, female gender has been reported as 
a possible risk factor for a specific etiology in 
a prospective study on 453 patients with acute 
pericarditis (mean age 52, 46% women) [4,10]. 
Unfortunately, there are no specific data avail-
able on the different etiologies of pericarditis 
according to gender. Considering the overall 
population including males, a specific cause was 
found in 76 out of 453 patients (16.8%) in the 
cited study: autoimmune in 33 patients (7.3%), 
neoplastic in 23 patients (5.1%), tuberculous in 
17 patients (3.8%) and purulent in three patients 
(0.7%). In a multivariable analysis, women (haz-
ard ratio [HR]: 1.67) and patients with fever 
>38°C (HR: 3.56), subacute course (HR: 3.97), 
large effusion or tamponade (HR: 2.15), and 
failure of aspirin or of  NSAIDs (HR: 2.50) were 
at increased risk of specific causes.
Cases with pericarditis related to SID are 
associated with more recurrences than idiopathic 
ones; on this basis, women may have more recur-
rences than men [10]. In a multivariable analysis, 
women (HR: 1.65) and patients with large effu-
sion or tamponade (HR: 2.51) as well as fail-
ure of aspirin or NSAIDs (HR: 5.50) were at 
increased risk of complications. A list of possible 
poor prognostic predictors in acute pericarditis 
is reported in Box 1.
The estimated incidence of pericardial involve-
ment in more common SID is variable and 
reported in TaBle 1. There are no specific gender 
Pericarditis is relatively common in clinical prac-
tice and may present as an isolated disease or as 
a manifestation of a systemic disease [1,2]. Few 
epidemiological data have been published. A 
reported incidence is 27.7 cases per 100,000 pop-
ulation per year in an urban Italian area [3]. The 
clinical diagnosis of pericarditis is relatively easy 
and based on clinical criteria, while the etiology 
search is more challenging and difficult in the 
clinical setting. Most cases are classified as idio-
pathic using a conventional diagnostic approach 
in developed countries with a low prevalence of 
tuberculosis [4–6]. Systemic inflammatory dis-
eases (SID) and post pericadiotomy or postinjury 
syndromes (5–10% of all unselected cases), neo-
plastic pericardial disease (5%) and tuberculous 
pericarditis (<5%) are the more common spe-
cific etiologies recorded in unselected series on 
pericarditis. The prognosis and the risk of com-
plication are related to the etiology, and idio-
pathic cases generally have good outcomes [7]. 
Recurrent pericarditis is the most common com-
plication of the disease affecting approximately 
30% of patients with acute pericarditis [4,7].
There is no specific gender predisposition to 
pericarditis, although women may be prone to 
specific etiologies, such as autoimmune systemic 
diseases that predispose women to more recur-
rences and complications [8–10]. The aim of the 
present paper is to review the management of peri-
carditis in women. Specific gender issues include 
the management of pericarditis during pregnancy 
and lactation [11,12] will be reviewed. Potentially 
relevant studies published up to January 2012 
were searched in BioMedCentral, the Cochrane 
Collaboration Database of Randomized Trials, 
ClinicalTrials.gov, EMBASE, Google Scholar, 
MEDLINE/PubMed and Scopus, including a 
comprehensive Medline search with the MeSH 
terms ‘pericarditis’ with and without sex limits. 
Articles were selected on the basis of their clinical 
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differences in types of pericardial involvement, 
although women are more commonly affected 
by a SID than men. The management approach 
does not differ according to the presence or 
absence of a SID [13].
Clinical presentation & diagnosis
Pericarditis may be acute (first attack), recurrent 
and sometimes chronic with an arbitrary term 
>3 months.
Chest pain, usually pleuritic, is the more com-
mon reported symptom of pericarditis (TaBle 2) 
and usually the main cause of presentation [9]. 
Typical ‘pericarditic’ chest pain is exacerbated by 
inspiration or coughing. On the contrary, pain is 
alleviated when the patient sits up and leans for-
ward because of the reduced pressure on the pari-
etal pericardium, with reduced friction between 
pericardial layers. In some cases, chest pain may 
be oppressive with possible irradiation to shoul-
ders. In such cases the differential diagnosis with 
ischemic chest pain may be difficult. Specific 
conditions to be ruled out include myocardial 
ischemia, pulmonary embolism, aortic dissec-
tion, pleuritis, pneumothorax, gastroesopha-
geal reflux disease and musculo skeletal pain [9]. 
Dyspnea is reported in a half of cases as well as 
palpitations generally related to supraventricular 
arrhythmias. The pathognomonic physical sign 
of pericarditis is the pericardial friction rub, usu-
ally evanescent and reported in a third of cases. 
Increased friction between inflamed pericardial 
layers is considered the main cause of the symp-
tom, although it may be present with pericardial 
effusion. Pericardial rubs occur during the maxi-
mal movement of the heart within the pericar-
dial sac; thus, the rub can be heard during atrial 
systole, ventricular systole and the rapid-filling 
phase of the ventricle (three-component rub). 
However, the rub may be present only during 
one (one component) or two phases (two compo-
nents) of the cardiac cycle. Pericardial rubs are of 
scratching or grating quality and appear superfi-
cial and are best heard with the diaphragm of the 
stethoscope. The intensity frequently increases 
after application of firm pressure with the dia-
phragm, during held inspiration, and with the 
patient leaning forward. The rub may be local-
ized or widespread. Pericardial rubs are unaf-
fected by respiration and this feature is useful for 
the differential diagnosis with pleural rubs [9–16].
ECG changes include widespread ST-elevation 
and PR depression (usually the first ECG change) 
and are reported in most cases (Figure 1), although 
a typical evolution is recorded in only 60% of 
cases (typical evolution includes four stages: 
stage I: diffuse ST-segment elevation; stage II: 
normalization of the ST segment; stage III: 
widespread T-wave inversion; and stage IV: nor-
malization of the T waves). ECG changes are 
affected by anti-inflammatory therapy, which 
may accelerate either evolution or resolution. 
Sustained arrhythmias are uncommon in the 
absence of a significant myocardial involvement 
or concomitant heart disease [3,14].
Box 1. Major clinical poor prognostic predictors in acute pericarditis.
• Fever >38°C
• Subacute onset
• Large pericardial effusion
• Cardiac tamponade
• Lack of response to aspirin or NSAIDs after at least 1 week of therapy
Adapted from [9].
Table 1. Estimated frequency and type of pericardial involvement in more common 
systemic inflammatory diseases.
Systemic disease and 
pericardial involvement
Estimated frequency (%) Type of involvement
Connective tissue diseases
Systemic lupus erythematosus >50 Pericardial effusion, pericarditis
Rheumatoid arthritis 10–30 Pericardial effusion (30%), 
pericarditis (10%)
Systemic sclerosis Symptomatic (<20), overall 
(>60)
Pericardial effusion, pericarditis
Polymyositis and dermatomyositis <10 Pericarditis, pericardial effusion, 
cardiac tamponade (case reports)
Mixed connective tissue disease 10–30 Pericarditis, pericardial effusion
Sjögren syndrome <30 Pericarditis
Behçet disease Rare Pericarditis
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Echocardiographic findings are generally 
nonspecific. A pericardial effusion has been 
reported in approximately a half of patients 
with acute pericarditis [9,15,16]. Transthoracic 
echo cardiography allows a quick assessment of 
the presence and hemodynamic importance of 
pericardial effusion. In clinical practice a com-
mon semiquantitative classification of pericar-
dial effusion is based on the estimation of peri-
cardial effusion echo-free spaces at the onset of 
the QRS complex in diastole (Figure 2). Cardiac 
tamponade is not common in viral/idiopathic 
cases (<5%), while it is commonly associated 
with a neoplastic or bacterial etiology [7].
Gender-specific issues for management: 
pregnancy & lactation
The most common form of pericardial involve-
ment is isolated pericardial effusion, which is 
usually a benign condition recorded by the third 
trimester in approximately 40% of pregnancies 
[12,17]. Acute pericarditis is the second most com-
mon form of pericardial involvement during 
pregnancy, although the exact frequency of the 
disease is unknown in the setting of pregnancy. 
Idiopathic pericarditis is the usual diagnosis in 
this setting, although a systemic autoimmune 
disease may be an alternative cause especially in 
cases with significant effusions or cardiac tam-
ponade at the initial presentation, particularly 
for systemic lupus erythematosus [13]. During 
pregnancy, cardiac tamponade manifestations 
may be attenuated by the physiologic increase 
of blood volume. On this basis, a pregnant 
woman is usually able to better tolerate a large 
effusion compared with an age-matched non-
pregnant woman. On the contrary, pregnant 
women are less tolerant in the case of initial 
constriction [17].
Other etiologies are less common. 
Tuberculosis is an important cause in devel-
oping countries, where the disease is often 
associated with HIV infection, as well as in 
immigrants. Neoplastic pericardial disease is 
rare, with breast cancer being the most com-
mon malignancy to be diagnosed during preg-
nancy, often at an advanced stage and with a 
high mortality [18].
Few data have been published on pericar-
ditis during pregnancy. At present, the largest 
published series of pregnant women with acute 
pericarditis included only six women (mean 
age 30 years, mean gestational age at delivery 
38 weeks and mean birth weight 2839 g), all 
with idiopathic etiology [11]. Four women were 
treated with 800 mg aspirin three-times daily. 
Aspirin was stopped at 20 weeks in three women 
and continued until delivery in one case. All 
women were treated with prednisone at low 
to moderate doses; four women received pred-
nisone throughout pregnancy, and two cases 
only during the third trimester. Five pregnan-
cies (>80%) were uneventful, with one case of 
HELLP syndrome in the woman who continued 
aspirin until delivery. The HELLP syndrome 
refers to a syndrome characterized by hemolysis 
with a microangiopathic blood smear, elevated 
liver enzymes and a low platelet count, occurring 
in less than 1% of normal pregnancies [19]. All 
infants had a good outcome. Recurrences rates 
were similar to nonpregnant cases (20–25%) 
after a mean follow-up of 21 months. These 
data show that pregnancies complicated by peri-
carditis generally have a good prognosis with 
event rates similar to nonpregnant women. The 
outcome is more correlated to the underlying 
etiology rather than pericarditis itself.
Table 2. Symptoms and clinical findings at presentation in acute 
pericarditis (data based on personal unselected series).
Symptom/sign Frequency (%)
Chest pain >95
Dyspnea 50
Palpitations 40–60
Weakness 25–35
Pericardial rubs 25–40
ST-segment elevation on ECG 70–90
Pericardial effusion 40–60
Cardiac tamponade† 5
†Diagnosis based on clinical findings supported by ECG.
Adapted from [15].
Figure 1. ECG in a woman with acute pericarditis at presentation in the 
emergency department. The patient was affected by pericarditis related to 
systemic lupus erythematosus.
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The proposed treatment protocol included 
aspirin being gradually stopped at 20 weeks 
of gestation, plus low dosages of prednisone 
if needed throughout pregnancy and lactation 
(TaBle 3), especially for recurrent cases, with very 
gradual tapering after delivery.
In regard to pericarditis, the reported out-
come has been relatively better than that usually 
reported in nonpregnant women with a very low 
recurrence rate (<20%) [20]. This may be due 
to the fact that no corticosteroid tapering was 
attempted during pregnancy.
Diagnostic issues
During pregnancy the main diagnostic issue is 
to avoid diagnostic testing that may be harm-
ful to the fetus, in particular avoiding expo-
sure to radiation. Echocardiography remains 
the imaging method of choice for diagnosis, 
follow-up and guidance for pericardiocente-
sis [21]. As for the general population of peri-
carditis patients, high-risk features at presenta-
tion include large pericardial effusion, cardiac 
tamponade, and a lack of response to aspirin or 
a NSAID [4,14,22].
A positive result for antinuclear antibodies 
(ANA), often as a fortuitous observation, may 
be a cause for concern in idiopathic recurrent 
pericarditis; this nonspecific finding may occur 
during pregnancy or in nonpregnant women. 
In an Italian study, ANA were detected in 53 
out of 122 (43.4%) patients with idiopathic 
recurrent pericarditis, and in only 12 out of 
122 (9.8%) controls (p < 0.001). Low titers 
(one out of 40 to one out of 80) were found in 
the majority of cases, while moderate positivity 
(one out of 160 to one out of 320) was more 
common in patients with a known rheumatic 
disease (26.7 vs 5.7%; p = 0.020). Women were 
at increased risk for ANA (odds ratio: 2.22; 
95% CI: 1.07–4.60; p = 0.033). During a mean 
follow-up of 32 months, complications and new 
diagnoses were similar in patients with or with-
out ANA positivity. Routine serologic testing for 
ANA suggests a source for recurrent pericarditis 
in less than 10% of cases, and in these cases 
other evidence typically suggests the underlying 
disease [23].
Therapy issues
In patients with a previous history of pericar-
dial disease, pregnancy should be planned in a 
phase of stable remission. Specific precautions 
include withdrawal of colchicine before concep-
tion, which is eventually substituted with aspirin 
and/or low-dose prednisone [24]. The appropri-
ate therapy (i.e., high-dose aspirin plus low-dose 
prednisone) should be reached and tested before 
conception, and then continued throughout 
pregnancy, with aspirin gradually tapered around 
week 20. Nowadays, the general outcomes of 
pregnancies in these women can be similar to that 
expected in the general population. Dedicated 
multidisciplinary teams are recommended to 
provide careful assessment and follow-up.
As for the general population of pregnant 
women, all medications that are not necessary 
Figure 2. Echocardiographic semiquantitative assessment of pericardial 
effusion. (A) Bidimensional image. (B) M-mode image. A small effusion is an 
echo-free space (anterior plus posterior) of <10 mm, a moderate effusion is an 
echo-free pericardial space of 10–20 mm and a large effusion is an echo-free space 
of >20 mm.
Table 3. Proposed treatment scheme for medical therapy of pericarditis during 
pregnancy.
Drug Pregnancy After delivery
<20 weeks >20 weeks During breastfeeding
Aspirin 
500–1000 mg every 8 h
First choice To be avoided Cautiously
NSAID Allowed To be avoided Allowed
Prednisone† Allowed‡ Allowed‡ Allowed‡
†Low-to-moderate doses are considered (<25 mg/day), usually from 2.5 to 15 mg/day.
‡Possible association with aspirin or a NSAID; the dose of aspirin of 100 mg/day or less is not useful as an anti-
inflammatory therapy (colchicine is contraindicated except for familial Mediterranean fever). Paracetamol 500–1000 mg 
every 8–12 h is always allowed. 
Adapted from [12].
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should be avoided. Current knowledge on drug 
safety during pregnancy and lactation is mainly 
based on animal data, human case reports and 
small series with inadvertent exposure. When 
pericarditis is treated in a pregnant woman the 
above recommendations should be considered.
NSAIDs
NSAIDs and aspirin are considered as first-line 
treatment in patients with pericarditis. These 
drugs can be continued until the second trimes-
ter [24] as nonselective COX inhibitors are not 
teratogenic and can be continued during the first 
and second trimester. There are no reliable data 
on selective COX-2 inhibitors, which should be 
avoided. After gestational week 20, all NSAIDs 
(except aspirin 100 mg/day or less) should be 
withdrawn because of possible constriction of 
the ductus arteriosus and impairment of fetal 
renal function. Most NSAIDs are excreted in 
small quantities into human breast milk. Several 
NSAIDs (i.e., ibuprofen, indomethacin, diclof-
enac, naproxen and piroxicam) are considered 
consistent with breastfeeding by the American 
Academy of Pediatrics [25]. Aspirin (>100 mg/day) 
should be considered with caution during breast-
feeding because of potential adverse effects to the 
infant. Exposure to the infant may be reduced if 
these drugs are given after breastfeeding [12,24].
Corticosteroids
Corticosteroids are commonly used during preg-
nancy. Corticosteroids are metabolized by the 
placenta with different efficiencies. Prednisone 
is actively metabolized and only 10% of the 
active drug reaches the fetus [26]. On the con-
trary, dexamethasone and betamethasone are less 
metabolized and may reach higher concentra-
tions in the fetus; for this reason they are used 
only for selected fetal indications (e.g., lung 
maturity induction and autoimmune congenital 
heart block). On this basis, prednisone is con-
sidered a category B drug in terms of its risk for 
pregnancy by the US FDA. Other corticosteroids 
are considered category C. Use of corticosteroids 
during pregnancy is associated with a three- to 
four-times increase in oral clefts.
Particularly during pregnancy, use of low doses 
of prednisone (i.e., 0.1–0.3 mg/kg/day) should 
be favored over higher doses because severe 
side effects are more common with high doses 
and may be responsible for more withdrawals, 
recurrences and disease-related hospitalizations 
according to a retrospective study on recurrent 
pericarditis, at present the largest available experi-
ence on this topic [27]. During pregnancy, specific 
feared corticosteroid dose-related side effects are 
hypertension, diabetes, premature rupture of 
membranes and prematurity, where prematurity 
is the first recognized cause of neonatal mortal-
ity and long-term neurological impairments in 
children. Breastfeeding is allowed during cortico-
steroid use, although high doses of corticosteroids 
should be postponed [12,24].
Colchicine
Colchicine has been traditionally prescribed for 
the treatment and prevention of gout attacks, but 
also for pericarditis management and prevention 
[28–32]. Colchicine has been recommended for the 
treatment of acute (class IIa recommendation) 
and recurrent pericarditis (class I recommenda-
tion) in the 2004 guidelines of the European 
Society of Cardiology based on experts consensus 
[8]. In the reported guidelines, the recommended 
therapeutic scheme included an attack dose with 
2 mg/day for 1–2 days followed by 1 mg/day. 
Subsequent randomized studies have confirmed 
this indication, showing that colchicine may 
improve remission rates and symptoms resolu-
tion during the acute attack and may halve recur-
rence rates when used for several months [29,30,32]. 
Tolerability is improved avoiding the use of load-
ing doses and starting with lower doses following 
weight-adjusted doses (i.e., 0.5 mg twice-daily for 
patients ≥70 kg, but only 0.5 mg once-daily for 
patients <70 kg).
Colchicine’s anti-inflammatory mechanism of 
action is only partially known. The drug, even 
when used at low oral doses (0.5–1.0 mg/day), is 
able to concentrate in white blood cells, especially 
granulocytes, inhibiting tubulin polymerization 
and interfering with microtubule function, which 
in turn interferes with leukocyte function. The 
high concentration of colchicine in white blood 
cells exerts anti-inflammatory effects mainly 
related to the interference with microtubules. 
Colchicine may also interfere with the mitotic 
spindle, affecting cell division. This effect is 
related to the possible negative effects on fertil-
ity, pregnancy, breastfeeding or childhood [33]. 
Colchicine is a highly poisonous alkaloid with a 
narrow therapeutic index and fatalities have been 
reported after oral ingestion. The severity and the 
mortality rate of the poisoning is directly related 
to the ingested dose. Reported mortality rates are 
10–50% with absorbed doses of 0.5–0.8 mg/kg 
and 100% with doses >0.8 mg/kg. Common tox-
icity symptoms include gastrointestinal symptoms 
at lower doses and initial stages followed by bone 
marrow aplasia, alopecia and circulatory failure in 
advanced cases with high doses. However, when 
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carefully prescribed at low oral doses, the drug is 
safe and efficacious. No significant adverse events 
have been recorded on fertility, pregnancy or fetal 
or child development in familial Mediterranean 
fever even after prolonged use [34,35]. Although 
potential teratogenicity cannot be absolutely 
excluded based on animal research [33], and 
amniocentesis with karyoting has been recom-
mended whenever colchicine is given during preg-
nancy [36], a recent Israeli paper has concluded 
that amniocentesis is no longer routinely recom-
mended in these women [37]. Thus, colchicine 
is contraindicated during pregnancy and lacta-
tion beyond specific indications, such as famil-
ial Mediterranean fever [33,36,37]. Gradual drug 
withdrawal is recommended before pregnancy.
Immunosuppressive drugs
Other immunosuppressive drugs are rarely indi-
cated in recurrent pericarditis [9,38]. Use of these 
treatments requires appropriate knowledge and 
cooperation with different specialists. Among 
these drugs, methotrexate and cyclo phosphamide 
are absolutely contraindicated and should be 
stopped 3 months before pregnancy, while other 
drugs (i.e., azathioprine, intravenous immuno-
globulins-IVIG and cyclosporine) may be used 
in selected cases.
Although rarely indicated, surgical thera-
pies (i.e., pericardiotomy and pericardiectomy) 
could be performed without risk for subsequent 
pregnancies [39].
Future perspective
Management of pericardial diseases is becom-
ing increasingly evidence based because of the 
growing number of clinical researches and trials 
[40]. However, further basic and clinical research 
is needed to improve the understanding of the 
pathophysiology of pericarditis, especially for 
recurrences, and to improve diagnostic tools 
to better address the etiologic search in order 
to develop targeted therapies. In addition, 
further clinical trials and prospective cohort 
and case–control studies are going to provide 
additional data on indication, dosing and treat-
ment lengths in order to have more evidence 
based approaches to therapies [9]. Additional 
case series and registries on pericardial diseases 
during pregnancy are needed to improve the 
management of these conditions, since this 
condition has been excluded in clinical trials 
or is only poorly reported in current available 
literature.
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Executive summary
• Pericarditis is relatively common in clinical practice and may present as an isolated disease or as a manifestation of a systemic disease.
• The clinical diagnosis of pericarditis is relatively easy and based on clinical criteria, while the etiology search is more challenging and 
difficult in the clinical setting, and most cases are classified as idiopathic using a conventional diagnostic approach in developed 
countries with a low prevalence of tuberculosis.
• There is no specific gender predisposition to pericarditis, although women may be prone to specific etiologies, such as autoimmune 
systemic diseases that predispose women to more recurrences and complications.
• Pericarditis may be acute (first attack), recurrent and sometimes chronic with an arbitrary term of >3 months. Chest pain, usually 
pleuritic, is the most common reported symptom of pericarditis, and usually the main cause of presentation.
• Specific conditions to be ruled out include myocardial ischemia, pulmonary embolism, aortic dissection, pleuritis, pneumothorax, 
gastroesophageal reflux disease and musculoskeletal pain.
• Gender-specific issues for pericarditis management in women include pregnancy and lactation.
• Acute pericarditis is the second more common form of pericardial involvement during pregnancy after isolated pericardial effusion, 
which is usually a benign condition recorded by the third trimester in approximately 40% of pregnancies.
• Idiopathic pericarditis is the usual diagnosis in this setting, although a systemic autoimmune disease may be an alternative cause 
especially in cases with significant effusions or cardiac tamponade at the initial presentation.
• For pregnant women the diagnostic approach is aimed at reducing useless investigations that may be harmful for the fetus, especially 
avoiding the exposure to radiation. ECG is the imaging method of choice for diagnosis, follow-up and guidance for pericardiocentesis.
• After gestational week 20, all NSAIDs (except aspirin at less than 100 mg/day) can cause constriction of the ductus arteriosus and 
impair fetal renal function and should be withdrawn in any case at gestational week 32. Low-to-medium doses of prednisone are 
allowed during all pregnancy and breast feeding. Colchicine is generally contraindicated during pregnancy, except in patients with 
familial Mediterranean fever or other compelling indications.
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